James Breitmeyer

Insider profile

Currently holds positions in Zogenix Inc and Oncternal Therapeutics Inc

Performance

Overall performance
2.9
Performance over holding periods
2.9
30 days 90 days 120 days
Average return 6% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
4 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Independent Director Zogenix Inc Jan. 1, 2017 -
President, Chief Executive Officer Oncternal Therapeutics Inc June 7, 2019 -
Director Zogenix Inc March 25, 2014 - Jan. 1, 2017
James Breitmeyer's trades of Oncternal Therapeutics Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Purchase
Price
121.65
Quantity 73,077 -27.7%
Value US$584,828
Transaction date
Purchase
Price
83.33
Quantity 51,992 -36.8%
Value US$3,200,908
Transaction date
Purchase
Price
470.10
Quantity 83,905 -5.1%
Value US$2,081,218
US Zogenix Inc (ZGNX)
Transaction date
Planned sale
Price
50.00
Quantity 5,000 -80.0%
Value US$250,000
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2023-04-17 2023-04-14
B Purchase
73,077 -27.7%
121.65
US$584,828 		73,077 -27.7% 121.65 US$584,828
2023-04-17 2023-04-14
B Purchase
51,992 -36.8%
83.33
US$3,200,908 		51,992 -36.8% 83.33 US$3,200,908
2023-04-17 2023-04-13
B Purchase
83,905 -5.1%
470.10
US$2,081,218 		83,905 -5.1% 470.10 US$2,081,218
2022-01-31 2022-01-27
B Purchase
25,000 +116.0%
1.68
US$42,080 		25,000 +116.0% 1.68 US$42,080
2019-11-27 2019-11-25
US Zogenix Inc (ZGNX)
PlS Planned sale
5,000 -80.0%
50.00
US$250,000 		5,000 -80.0% 50.00 US$250,000